MARC보기
LDR02130nam u200397 4500
001000000418873
00520190215163225
008181129s2017 |||||||||||||||||c||eng d
020 ▼a 9780438097766
035 ▼a (MiAaPQ)AAI10901832
035 ▼a (MiAaPQ)OhioLINK:osu1510592650256558
040 ▼a MiAaPQ ▼c MiAaPQ ▼d 247004
0820 ▼a 574
1001 ▼a Ruppert Stark, Amy S.
24510 ▼a Early Clinical Trial Design Recommendations in Oncology Based on Overall Success across Phases I, II, and III.
260 ▼a [S.l.]: ▼b The Ohio State University., ▼c 2017.
260 1 ▼a Ann Arbor: ▼b ProQuest Dissertations & Theses, ▼c 2017.
300 ▼a 204 p.
500 ▼a Source: Dissertation Abstracts International, Volume: 79-12(E), Section: B.
500 ▼a Adviser: Abigail Shoben.
5021 ▼a Thesis (Ph.D.)--The Ohio State University, 2017.
520 ▼a Conventionally, drug development has spanned three distinct phases, and the success rate for experimental drugs across phases has been less than 15% (Hay, Thomas, Craighead, Economides, and Rosenthal, 2014). Despite increased options for nonstan
520 ▼a Phase I, II, and III trials were simulated for clinical scenarios defined by eight toxicity profiles and two nondecreasing efficacy profiles. Early results showed that correctly selecting the maximum tolerated dose (MTD) greatly impacted overall
520 ▼a Based on our results, we make the following recommendations for design selection when data informing the shape of the dose-toxicity curve exist. If a large jump in toxicity between dose levels is expected, we recommend the standard 3+3 design, w
590 ▼a School code: 0168.
650 4 ▼a Biostatistics.
690 ▼a 0308
71020 ▼a The Ohio State University. ▼b Biostatistics.
7730 ▼t Dissertation Abstracts International ▼g 79-12B(E).
773 ▼t Dissertation Abstract International
790 ▼a 0168
791 ▼a Ph.D.
792 ▼a 2017
793 ▼a English
85640 ▼u http://www.riss.kr/pdu/ddodLink.do?id=T15000279 ▼n KERIS ▼z 이 자료의 원문은 한국교육학술정보원에서 제공합니다.
980 ▼a 201812 ▼f 2019
990 ▼a ***1012033